Carmat SAS (ALCAR) soared as much as 43 percent after the company’s artificial heart was implanted in a patient for the first time last week.
The surgery took place at Georges Pompidou hospital in Paris on Wednesday and two days later the patient was speaking with his family, the company said late Friday.
Carmat rose 27 percent to 130.50 euros at 9:18 a.m. in Paris, giving the company a market value of 553.7 million euros ($757.4 million). That’s the biggest intraday gain in three months. Volume was more than six times the three-month daily average. Before today, the stock had dropped 19 percent this year.
The maker of medical devices, based in Velizy-Villacoublay near Paris, designed the prosthetic organ for patients with terminal heart failure who can’t get a human heart for a transplant. About 17.3 million people died from cardiovascular disease in 2008 and that number may rise to 23.3 million by 2030, the World Health Organization estimates.
Regulators have allowed Carmat to test the device by implanting it in four patients in France. The company’s scientific committee then plans to meet to review the cases.
The heart weighs 750 grams (1.7 pounds) and will cost on average 140,000 euros to 160,000 euros, Chief Executive Officer Marcello Conviti said in an interview this year. The implant is designed to conform as much as possible to the human heart’s anatomy, featuring right and left ventricles and reproducing the muscle’s contraction.
The company’s founder, cardiac surgeon Alain Carpentier, who also is part of Carmat’s scientific advisory board, successfully developed heart valves in the past.
To contact the reporter on this story: Marthe Fourcade in Paris at email@example.com
To contact the editor responsible for this story: Kristen Hallam at firstname.lastname@example.org